{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T12:49:36Z","timestamp":1737895776028,"version":"3.33.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s11938-008-0002-1","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T14:40:23Z","timestamp":1201704023000},"page":"11-18","source":"Crossref","is-referenced-by-count":6,"title":["Opioid-induced bowel dysfunction"],"prefix":"10.1007","volume":"11","author":[{"given":"Howard Y.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"2_CR1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1572-0241.2005.40925.x","volume":"100","author":"D. Ramkumar","year":"2005","unstructured":"Ramkumar D, Rao SS: Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005, 100:936\u2013971.","journal-title":"Am J Gastroenterol"},{"key":"2_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1365-2036.1998.00336.x","volume":"12","author":"J.W. McRorie","year":"1998","unstructured":"McRorie JW, Daggy BP, Morel JG, et al.: Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998, 12:491\u2013497.","journal-title":"Aliment Pharmacol Ther"},{"key":"2_CR3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gut.44.2.226","volume":"44","author":"A. Attar","year":"1999","unstructured":"Attar A, Lemann M, Ferguson A, et al.: Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999, 44:226\u2013230.","journal-title":"Gut"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/BF02087913","volume":"41","author":"E. Corazziari","year":"1996","unstructured":"Corazziari E, Badiali D, Habib FI, et al.: Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996, 41:1636\u20131642.","journal-title":"Dig Dis Sci"},{"key":"2_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1532-5415.1978.tb01967.x","volume":"26","author":"J.F. Sanders","year":"1978","unstructured":"Sanders JF: Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriatr Soc 1978, 26:236\u2013239.","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl1","key":"2_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004836-198100031-00005","volume":"3","author":"P. Bass","year":"1981","unstructured":"Bass P, Dennis S: The laxative effects of lactulose in normal and constipated subjects. J Clin Gastroenterol 1981, 3(Suppl 1):23\u201328.","journal-title":"J Clin Gastroenterol"},{"key":"2_CR7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/j.1552-4604.1997.tb04264.x","volume":"37","author":"M.D. Freedman","year":"1997","unstructured":"Freedman MD, Schwartz HJ, Roby R, Fleisher S: Tolerance and efficacy of polyethylene glycol 3350\/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol 1997, 37:904\u2013907.","journal-title":"J Clin Pharmacol"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1572-0241.2007.01199.x","volume":"102","author":"J.A. DiPalma","year":"2007","unstructured":"DiPalma JA, Cleveland MV, McGowan J, Herrera JL: A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007, 102:1436\u20131441.","journal-title":"Am J Gastroenterol"},{"key":"2_CR9","doi-asserted-by":"crossref","unstructured":"Johanson JF, Morton D, Geenen J, Ueno R: Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2007 [Epub ahead of print.]","DOI":"10.1111\/j.1572-0241.2007.01524.x"},{"key":"2_CR10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.283.3.367","volume":"283","author":"C.S. Yuan","year":"2000","unstructured":"Yuan CS, Foss JF, O\u2019Connor M, et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000, 283:367\u2013372.","journal-title":"JAMA"},{"key":"2_CR11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0009-9236(97)90197-1","volume":"61","author":"C.S. Yuan","year":"1997","unstructured":"Yuan CS, Foss JF, Osinski J, et al.: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997, 61:467\u2013475.","journal-title":"Clin Pharmacol Ther"},{"key":"2_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mcp.2000.105037","volume":"67","author":"C.S. Yuan","year":"2000","unstructured":"Yuan CS, Foss JF, O\u2019Connor M, et al.: Effects of entericcoated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000, 67:398\u2013404.","journal-title":"Clin Pharmacol Ther"},{"key":"2_CR13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.284.11.1383","volume":"284","author":"C.S. Yuan","year":"2000","unstructured":"Yuan CS, Foss JF: Oral methylnaltrexone for opioid-induced constipation. JAMA 2000, 284:1383\u20131384.","journal-title":"JAMA"},{"issue":"Suppl2","key":"2_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1743-3150.2004.00555.x","volume":"16","author":"B. Greenwood-Van Meerveld","year":"2004","unstructured":"Greenwood-Van Meerveld B, Gardner CJ, Little PJ, et al.: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004, 16(Suppl 2):46\u201353.","journal-title":"Neurogastroenterol Motil"},{"key":"2_CR15","first-page":"1496","volume":"3","author":"I.A. Azodo","year":"2002","unstructured":"Azodo IA, Ehrenpreis ED: Alvimopan (Adolor\/GlaxoSmithKine). Curr Opin Investig Drugs 2002, 3:1496\u20131501.","journal-title":"Curr Opin Investig Drugs"},{"key":"2_CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpain.2004.12.001","volume":"6","author":"D.M. Paulson","year":"2005","unstructured":"Paulson DM, Kennedy DT, Donovick RA, et al.: Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction\u2014a 21-day treatment-randomized clinical trial. J Pain 2005, 6:184\u2013192.","journal-title":"J Pain"},{"key":"2_CR17","unstructured":"Postoperative ileus (POI) clinical development program. Adolor Corporation website. http:\/\/www.adolor.com\/entereg_poi_development.htm . Accessed November 12, 2007."},{"key":"2_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2036.2006.03150.x","volume":"25","author":"E.K. Tan","year":"2007","unstructured":"Tan EK, Cornish J, Darzi AW, Tekkis PP: Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther 2007, 25:47\u201357.","journal-title":"Aliment Pharmacol Ther"},{"key":"2_CR19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.sla.0000232538.72458.93","volume":"245","author":"C.P. Delaney","year":"2007","unstructured":"Delaney CP, Wolff BG, Viscusi ER, et al.: Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg 2007, 245:355\u2013363.","journal-title":"Ann Surg"},{"key":"2_CR20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.15.5.541","volume":"15","author":"C.S. Yuan","year":"2006","unstructured":"Yuan CS, Israel RJ: Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006, 15:541\u2013552.","journal-title":"Expert Opin Investig Drugs"},{"key":"2_CR21","first-page":"127","volume":"46","author":"I. Moerman","year":"1995","unstructured":"Moerman I, Franck P, Camu F: Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol Belg 1995, 46:127\u2013132.","journal-title":"Acta Anaesthesiol Belg"},{"key":"2_CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0306-4522(97)00227-3","volume":"81","author":"D. Bagnol","year":"1997","unstructured":"Bagnol D, Mansour A, Akil H, Watson SJ: Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 1997, 81:579\u2013591.","journal-title":"Neuroscience"},{"key":"2_CR23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0024-3205(96)00647-9","volume":"60","author":"N. Friese","year":"1997","unstructured":"Friese N, Chevalier E, Angel F, et al.: Reversal by kappagonists of peritoneal irritation-induced ileus and visceral pain in rats. Life Sci 1997, 60:625\u2013634.","journal-title":"Life Sci"},{"key":"2_CR24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0016-5085(96)70064-1","volume":"111","author":"J.N. Sengupta","year":"1996","unstructured":"Sengupta JN, Su X, Gebhart GF: Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996, 111:968\u2013980.","journal-title":"Gastroenterology"},{"key":"2_CR25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0705763","volume":"141","author":"P.J. Riviere","year":"2004","unstructured":"Riviere PJ: Peripheral kappa-opioid agonsits for visceral pain. Br J Pharmacol 2004, 141:1331\u20131334.","journal-title":"Br J Pharmacol"},{"key":"2_CR26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0016-5085(99)70226-X","volume":"116","author":"M. Delvaux","year":"1999","unstructured":"Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116:38\u201345.","journal-title":"Gastroenterology"},{"key":"2_CR27","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/BF02209014","volume":"40","author":"M. Dapoigny","year":"1995","unstructured":"Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995, 40:2244\u20132249.","journal-title":"Dig Dis Sci"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/gut.41.5.664","volume":"41","author":"N.W. Read","year":"1997","unstructured":"Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664\u2013668.","journal-title":"Gut"},{"key":"2_CR29","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/00004836-200207001-00011","volume":"35","author":"M.J. Callahan","year":"2002","unstructured":"Callahan MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002, 35:S58\u2013S67.","journal-title":"J Clin Gastroenterol"},{"key":"2_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3959(02)00259-2","volume":"101","author":"J.C. Eisenach","year":"2003","unstructured":"Eisenach JC, Carpenter R, Curry R: Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003, 101:89\u201395.","journal-title":"Pain"},{"key":"2_CR31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1152\/jn.2000.83.2.963","volume":"83","author":"X. Su","year":"2000","unstructured":"Su X, Julia V, Gebhart GF: Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 2000, 83:963\u2013970.","journal-title":"J Neurophysiol"},{"key":"2_CR32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(24)37421-X","volume":"285","author":"M.B. Burton","year":"1998","unstructured":"Burton MB, Gebhart GF: Effects of kappa-opioid receptor agaonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998, 285:707\u2013715.","journal-title":"J Pharmacol Exp Ther"},{"key":"2_CR33","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.cgh.2007.07.011","volume":"5","author":"L.A. Szarka","year":"2007","unstructured":"Szarka LA, Camilleri M, Burton D, et al.: Efficacy of ondemand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007, 5:1268\u20131275.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2_CR34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bjp.0701874","volume":"124","author":"W. Binder","year":"1998","unstructured":"Binder W, Walker JS: Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis. Br J Pharmacol 1998, 124:647\u2013654.","journal-title":"Br J Pharmacol"},{"key":"2_CR35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/rheumatology\/40.9.1013","volume":"40","author":"K.A. Bush","year":"2001","unstructured":"Bush KA, Kirkham BW, Walker JS: The kappa-opioid agonist, asimadoline, alters cytokine gene expression in adjuvant arthritis. Rheumatology (Oxford) 2001, 40:1013\u20131021.","journal-title":"Rheumatology (Oxford)"},{"key":"2_CR36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1054\/npep.2000.0813","volume":"34","author":"J.S. Walker","year":"2000","unstructured":"Walker JS, Scott C, Bush KA, Kirkham BW: Effects of the peripherally selective kappa-opioid asimadoline, on substance P and CGRP mRNA expression in chronic arthritis of the rat. Neuropeptides 2000, 34:193\u2013202.","journal-title":"Neuropeptides"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-008-0002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-008-0002-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-008-0002-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T12:09:51Z","timestamp":1737893391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-008-0002-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s11938-008-0002-1","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"type":"print","value":"1092-8472"},{"type":"electronic","value":"1534-309X"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}